Login to Your Account

Full 'Spectrum' of reactions as Evomela gets CRL

By Marie Powers
Staff Writer

Friday, October 23, 2015

Shares of Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) fell to a one-year low of $4.89 Friday morning after the company said it received a complete response letter (CRL) from the FDA on Evomela (melphalan). The high-dose intravenous formulation of Captisol-enabled (CE) melphalan is designed as a conditioning treatment prior to autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription